Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.

Cancer cell - 13 May 2024

Diepstraten Sarah T, Yuan Yin, La Marca John E, Young Savannah, Chang Catherine, Whelan Lauren, Ross Aisling M, Fischer Karla C, Pomilio Giovanna, Morris Rhiannon, Georgiou Angela, Litalien Veronique, Brown Fiona C, Roberts Andrew W, Strasser Andreas, Wei Andrew H, Kelly Gemma L

Abstract excerpt

TP53-mutant blood cancers remain a clinical challenge. BH3-mimetic drugs inhibit BCL-2 pro-survival proteins, inducing cancer cell apoptosis. Despite acting downstream of p53, functional p53 is required for maximal cancer cell killing by BH3-mimetics through an unknown mechanism. Here, we report p53 is activated following BH3-mimetic induced mitochondrial outer membrane permeabilization, leading to BH3-only...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Hematologic Neoplasms

Share to Peptide Fragments

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-bcl-2

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 38670091
DOI: 10.1016/j.ccell.2024.04.004

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.PMID 38670091Read ↗

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemiasSemantic proximity Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.Semantic proximity Read ↗

STING agonists in combination with epigenetic drugs potentiate ZNFX1-driven inflammatory necroptosis in <i>TP53</i> -mutated AMLSemantic proximity Read ↗

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockadeSemantic proximity Read ↗

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugsSemantic proximity Read ↗

p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapySemantic proximity Read ↗

STAT3 inhibitor STAT-IN-12 induces apoptosis in mutant-p53 MDA-MB-435 and MDA-MB-231 breast cancer cell lines.Semantic proximity Read ↗

STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compoundsSemantic proximity Read ↗

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.